Plus Therapeutics, Inc. has announced that it received a notice from The Nasdaq Stock Market LLC regarding non-compliance with the minimum bid price requirement. The company's common stock has closed below $1.00 per share for 30 consecutive business days, failing to meet Nasdaq Listing Rule 5550(a)(2). This notice does not immediately affect the listing or trading of Plus Therapeutics' stock. The company has been given until November 12, 2025, to regain compliance by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. If unable to meet this deadline, Plus Therapeutics may qualify for an additional 180-day compliance period, provided it meets other Nasdaq listing requirements and plans to address the deficiency, potentially through a reverse stock split. The company is actively monitoring the situation and considering options to regain compliance, although there is no guarantee of success.